Address: 50 Soldiers Field Place, Boston, MA 02135 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
At Medicilon, chemistry and biology are integrated in every project we undertake. Our medicinal chemistry team is capable of flexibly applying computer chemistry to assist compound design process. We apply advanced drug discovery technologies, including proteolysis-targeting chimera (PROTAC), and antibody drug conjugation (ADC) to facilitate your projects.
We are also proud of our rich experience in innovative design and patent strategies that complement our technologies. In addition, we utilise responsive project management and effective communication to help optimize project delivery.
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA